KV Pharma To Shell Out $17M In FCA Settlement

Law360, Washington (December 6, 2011, 6:42 PM EST) -- KV Pharmaceutical Co. agreed Tuesday to pay $17 million to resolve a former subsidiary's role in a long-running False Claims Act qui tam action alleging it wrongly reported to Medicaid and Medicare programs that two drugs were qualified for coverage under the federal health care systems.

St. Louis-based KV was the parent company of now-defunct Ethex Corp., which allegedly filed the false reports for nitroglycerin extended-release capsules and hyoscyamine sulfate extended-release capsules, law enforcement officials said Tuesday.

“Today’s settlement underscores our commitment to pursuing pharmaceutical companies...
To view the full article, register now.



Case Information

Case Title

United States, ex rel v. Actavis Mid-Atlantic, et al

Case Number




Nature of Suit

Other Statutory Actions


Rya W. Zobel

Date Filed

August 29, 2002


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.